ING Groep NV Sells 114,777 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

ING Groep NV cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 57.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 85,988 shares of the medical research company’s stock after selling 114,777 shares during the quarter. ING Groep NV’s holdings in Thermo Fisher Scientific were worth $53,190,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Headlands Technologies LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter worth $32,000. TBH Global Asset Management LLC lifted its stake in shares of Thermo Fisher Scientific by 7.0% in the 1st quarter. TBH Global Asset Management LLC now owns 671 shares of the medical research company’s stock valued at $390,000 after acquiring an additional 44 shares during the last quarter. Lord Abbett & CO. LLC boosted its holdings in Thermo Fisher Scientific by 1.9% during the 1st quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock valued at $45,478,000 after acquiring an additional 1,480 shares during the period. Brighton Jones LLC grew its position in Thermo Fisher Scientific by 5.4% during the 1st quarter. Brighton Jones LLC now owns 4,057 shares of the medical research company’s stock worth $2,358,000 after acquiring an additional 209 shares during the last quarter. Finally, Great Lakes Retirement Inc. lifted its position in Thermo Fisher Scientific by 1.2% in the first quarter. Great Lakes Retirement Inc. now owns 4,446 shares of the medical research company’s stock valued at $2,584,000 after purchasing an additional 53 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 1.0 %

Shares of NYSE:TMO traded down $5.25 during trading on Thursday, reaching $536.65. 578,709 shares of the stock traded hands, compared to its average volume of 1,457,049. Thermo Fisher Scientific Inc. has a 52-week low of $463.99 and a 52-week high of $627.88. The stock has a market cap of $205.27 billion, a P/E ratio of 33.78, a price-to-earnings-growth ratio of 3.57 and a beta of 0.79. The stock has a 50-day moving average of $589.87 and a two-hundred day moving average of $583.04. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same quarter last year, the company earned $5.69 EPS. The company’s quarterly revenue was up .2% compared to the same quarter last year. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the transaction, the chief executive officer now owns 14,608 shares of the company’s stock, valued at approximately $8,076,178.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 9,000 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the completion of the transaction, the chief executive officer now directly owns 14,608 shares of the company’s stock, valued at approximately $8,076,178.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,150 shares of company stock worth $20,651,865 in the last ninety days. Insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. JPMorgan Chase & Co. upped their price objective on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Royal Bank of Canada cut their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Barclays reduced their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $649.33.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.